Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

Core Viewpoint - MediX announced that shareholder Chen Guoxing intends to reduce his holdings by up to 2,200,000 shares, representing 1.64% of the total share capital, due to personal funding needs [2] Summary by Sections Shareholder Holdings - As of the announcement date, Chen Guoxing holds 4,875,154 shares, accounting for 3.63% of the total share capital [2] - Together with his concerted actor Lin Changqing, they hold a total of 8,806,324 shares, which is 6.55% of the total share capital [2] Reduction Plan - The reduction will be executed through centralized bidding and block trading methods [2] - The implementation period for the reduction plan is within three months after the disclosure of the reduction plan, excluding the period prohibited by the China Securities Regulatory Commission and the Shanghai Stock Exchange [2]

Group 1: Company Buybacks - Longlide plans to repurchase company shares for no less than 56 million yuan [2] - Hanshuo Technology has obtained a commitment letter for a stock repurchase loan from a financial institution [2] - Prolo Pharmaceutical intends to use between 180 million to 360 million yuan to buy back company shares [2] Group 2: Company Sell-offs - Suda Co., Ltd. plans to reduce its holdings by no more than 3% [2] - Hunan Baiyin intends to reduce its holdings by no more than 1.95% [2] - Zimi Co., Ltd. plans to reduce its holdings by no more than 1% [2] - Zhongshui Fishery's third-largest shareholder has reduced its holdings by 2.5888 million shares, bringing its stake down to 5% [2] - We Online's investors plan to collectively reduce their holdings by no more than 5.94% [2] - Renmin Tongtai's controlling shareholder plans to reduce its holdings by no more than 1% [2] - Yanshiwei's fourth and fifth largest shareholders plan to reduce their holdings by no more than 1.5% and 1% respectively [2] - Langke Intelligent's shareholders plan to reduce their holdings by no more than 1.68% [2] - Yingben Co., Ltd.'s director plans to reduce his holdings by no more than 0.03% [2] - Sunshine Power has completed the implementation of share reduction plans by some directors and senior management [2] - Dipu Technology's shareholder plans to reduce his holdings by no more than 1.55% [2] - MediWest's shareholder plans to reduce his holdings by no more than 1.64% [2] - Huahai Qingke's shareholder plans to reduce his holdings by no more than 1% [2] - Liyuan Technology's shareholder plans to reduce his holdings by no more than 2.0303% [2] - New Emerging Equipment's shareholders plan to collectively reduce their holdings by no more than 3.13% [2] - Jinqiao Information's director plans to reduce his holdings by no more than 0.0675% [2] - Kanglongda's shareholder plans to reduce his holdings by no more than 3% [2]

Core Viewpoint - Medisi (688202.SH) announced that shareholder Chen Guoxing plans to reduce his holdings by a total of no more than 2.2 million shares, which accounts for up to 1.64% of the company's total share capital due to personal funding needs [1] Summary by Category - **Shareholder Actions** - Shareholder Chen Guoxing intends to reduce his stake through centralized bidding and block trading [1] - The total number of shares to be reduced is capped at 2.2 million [1] - **Impact on Company** - The reduction represents a maximum of 1.64% of the total share capital of the company [1]

Core Viewpoint - The announcement from Meidisi (688202) indicates that shareholder Chen Guoxing plans to reduce his stake in the company due to personal financial needs, which may impact the stock's market performance [2]. Summary by Sections Shareholder Actions - Chen Guoxing intends to reduce his holdings by up to 2.2 million shares, representing no more than 1.64% of the company's total equity [2]. - Currently, Chen Guoxing holds 4.8752 million shares, accounting for 3.63% of the total shares outstanding [2]. - Together with his concerted party Lin Changqing, they hold a total of 8.8063 million shares, which is 6.55% of the total equity [2].

Group 1 - The core point of the article is that Meidisi (688202.SH) announced a share reduction plan by shareholder Chen Guoxing due to personal funding needs [1] - Chen Guoxing intends to reduce a total of up to 2.2 million shares, which represents no more than 1.64% of the company's total share capital [1]

证券代码：688202 证券简称：美迪西 公告编号：2025-069 上海美迪西生物医药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，上海美迪西生物医药股份有限公司（以下简称"公司"） 股东陈国兴先生持有公司股份 4,875,154 股，占公司总股本的 3.63%，与其一致 行动人林长青先生合计持有公司股份 8,806,324 股股份，占公司总股本的 6.55%。 上述股份来源于公司 IPO 前取得的股份以及公司实施资本公积金转增股本， 陈国兴的股份已于 2022 年 11 月 7 日起解禁上市流通。 减持计划的主要内容 因股东自身资金需求，公司股东陈国兴拟通过集中竞价和大宗交易的方式减 持合计不超过所持公司股票 2,200,000 股，即不超过公司总股本的 1.64%，自减 持计划披露之日起 15 个交易日后的 3 个月内（根据中国证监会及上海证券交易 所规定禁止减持的期间除外）实施。 上述股份减持价格按减持实施时的市 ...

格隆汇11月19日｜美迪西公告，因股东自身资金需求，公司股东陈国兴拟通过集中竞价和大宗交易的方 式减持合计不超过所持公司股票2,200,000股，即不超过公司总股本的1.64%，自减持计划披露之日起15 个交易日后的3个月内实施。截至本公告披露日，上海美迪西生物医药股份有限公司股东陈国兴先生持 有公司股份4,875,154股，占公司总股本的3.63%，与其一致行动人林长青先生合计持有公司股份 8,806,324股股份，占公司总股本的6.55%。 ...

每经AI快讯，11月19日，美迪西(688202.SH)公告称，股东陈国兴因自身资金需求，拟通过集中竞价和 大宗交易方式减持不超过220.00万股，占公司总股本的1.64%。减持期间为2025年12月11日至2026年3月 10日，减持股份来源于IPO前取得及资本公积转增股本。 ...

Group 1 - The core viewpoint of the news is that Meidi Xi's stock has experienced fluctuations, with a year-to-date increase of 100.99% but a recent decline in the last five trading days by 8.94% [1] - As of November 19, Meidi Xi's stock price is 60.64 yuan per share, with a market capitalization of 8.147 billion yuan [1] - The company has seen a net outflow of main funds amounting to 458.48 thousand yuan, with significant selling pressure observed [1] Group 2 - Meidi Xi operates in the pharmaceutical and biotechnology sector, specifically in medical services and contract research organization (CRO) services [2] - For the period from January to September 2025, Meidi Xi reported revenue of 843 million yuan, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.6849 million yuan, showing a significant increase of 76.93% [2] - The number of shareholders increased by 27.83% to 16,500 as of September 30, with an average of 8,149 circulating shares per person, which decreased by 21.96% [2] Group 3 - Since its A-share listing, Meidi Xi has distributed a total of 158 million yuan in dividends, with 33.9365 million yuan paid out in the last three years [3]